Detalles de la búsqueda
1.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Breast Cancer Res
; 25(1): 103, 2023 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37653397
2.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Ann Oncol
; 32(8): 1015-1024, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34102253
3.
Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database.
Neoplasma
; 67(6): 1373-1383, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32614235
4.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 29(7): 1541-1547, 2018 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29718092
5.
[Reactive Lymphoid Hyperplasia of the Liver]. / Reaktivní lymfoidní hyperplazie jater.
Klin Onkol
; 30(4): 294-298, 2017.
Artículo
en Cs
| MEDLINE | ID: mdl-28832176
6.
[Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale]. / Hodnocení klinického benefitu protinádorových léku limitovaných na komplexní onkologická centra podle metodiky ESMO-MCBS.
Klin Onkol
; 30(5): 349-360, 2017.
Artículo
en Cs
| MEDLINE | ID: mdl-29031037
7.
[Magnetic resonance imaging in preoperative diagnosis of invasive lobular carcinomas of the breast - analysis of 230 cases]. / Magnetická rezonance v predoperacní diagnostice invazivních lobulárních karcinomu prsu - analýza 230 prípadu.
Rozhl Chir
; 96(8): 340-345, 2017.
Artículo
en Cs
| MEDLINE | ID: mdl-29058924
8.
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.
Ann Oncol
; 27(11): 2059-2066, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27573562
9.
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Ann Oncol
; 32(10): 1307, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412950
10.
[Pregnancy after Treatment of Breast Cancer]. / Tehotenství po lécbe karcinomu prsu.
Klin Onkol
; 29 Suppl 3: S23-28, 2016.
Artículo
en Cs
| MEDLINE | ID: mdl-28118721
11.
[Hereditary Breast and Ovarian Cancer Syndrome]. / Syndrom hereditárního karcinomu prsu a ovarií.
Klin Onkol
; 29 Suppl 1: S14-21, 2016.
Artículo
en Cs
| MEDLINE | ID: mdl-26691938
12.
[Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications]. / Sledování cirkulujících hladin estradiolu u pacientek s karcinomem prsu lécených inhibitory aromatázy - prínos v klinické praxi.
Klin Onkol
; 29 Suppl 3: S50-57, 2016.
Artículo
en Cs
| MEDLINE | ID: mdl-28118724
13.
[Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome]. / Doporucení rozsírení indikacních kriterií ke genetickému testování mutací v genech BRCA1 a BRCA2 u hereditárního syndromu nádoru prsu a ovarií.
Klin Onkol
; 29 Suppl 1: S9-13, 2016.
Artículo
en Cs
| MEDLINE | ID: mdl-26691937
14.
[Triple Negative Breast Cancer]. / Triple negativní karcinom prsu.
Klin Onkol
; 28(6): 405-15, 2015.
Artículo
en Cs
| MEDLINE | ID: mdl-26673990
15.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Ann Oncol
; 30(11): 1842, 2019 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31407010
16.
[Lobular breast cancer in man - case report and review of the literature]. / Lobulární karcinom prsu u muze - kazuistikaa prehled literatury.
Klin Onkol
; 27(2): 97-102, 2014.
Artículo
en Cs
| MEDLINE | ID: mdl-24739045
17.
[Precursors of breast cancer]. / Prekurzory karcinomu prsu.
Klin Onkol
; 26 Suppl: S7-12, 2013.
Artículo
en Cs
| MEDLINE | ID: mdl-24325156
18.
[Diagnostics of breast cancer in high-risk women - our own experience]. / Diagnostika nádoru prsu ve skupine rizikových zen - vlastní zkusenosti.
Klin Onkol
; 25 Suppl: S96-8, 2012.
Artículo
en Cs
| MEDLINE | ID: mdl-22920215
19.
[Li-Fraumeni syndrome - a proposal of complex prevention care for carriers of TP53 mutation with total-body MRI]. / Li-Fraumeni syndrom - návrh komplexní preventivní péce o nosice TP53 mutace s pouzitím celotelové magnetické rezonance.
Klin Onkol
; 25 Suppl: S49-54, 2012.
Artículo
en Cs
| MEDLINE | ID: mdl-22920207
20.
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.
Ann Oncol
; 22(3): 595-602, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20819780